5 results
The primary objective is to evaluate the safety of ReFacto AF in previously untreated patients (no prior exposure to factor products or any blood products) of less than 6 years of age.
The objectives are to evaluate:- The effect of Org 3236 on prostate volume compared to placebo;- The effect of Org 3236 on LUTS compared to placebo;- The effect of Org 3236 on urinary flow and postvoid residual volume compared toplacebo;- The effect…
DDAVP treatment combined with FVIII clotting factor concentrates in patients with mild hemophilia A.
Primary objectives:To assess the proportion of non-severe hemophilia A patients within FVIII target levels with the DDAVP and FVIII concentrate combination treatment in the first 72 hours after the start of combination treatment, without adding off-…
The purpose of this study is to investigate how safe and effective the new drug conbercept given as intravitreal injections (*study drug*) is when compared with Eylea® injections in patients with neovascular *wet* age-related macular degeneration (…
To investigate the reliability and feasibility of PK-guided prophylactic dosing of factor concentrates in hemophilia A and B patients (predictive performance).